Sanavia Oncology Inc.
Biotechnology company based in New York focused on discovery and preclinical development of immunotherapies that target drug‑resistant tumors. Uses integrated experimental and computational methods to identify cancer‑specific epitopes and generate targeted antibodies for preclinical validation.
Industries
N/A
Products
Proprietary discovery platform for cancer-specific epitopes
An integrated discovery platform combining sequencing, microscopy, structural modeling, and AI to identify cancer-specific epitopes and support antibody generation for drug-resistant tumors.
Proprietary discovery platform for cancer-specific epitopes
An integrated discovery platform combining sequencing, microscopy, structural modeling, and AI to identify cancer-specific epitopes and support antibody generation for drug-resistant tumors.
Services
Collaborative research and pharma partnerships
Partnerships with researchers, healthcare professionals, and organizations to advance oncology research and development.
Collaborative research and pharma partnerships
Partnerships with researchers, healthcare professionals, and organizations to advance oncology research and development.
Expertise Areas
- Immunotherapy discovery and preclinical development
- Epitope discovery and mapping
- Therapeutic antibody engineering
- Cancer drug resistance research
Key Technologies
- High-throughput sequencing
- Single-molecule super-resolution microscopy
- 3D protein structural modeling
- Artificial intelligence / machine learning